These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37530674)

  • 41. Prenatal diagnosis of disorders of fatty acid transport and mitochondrial oxidation.
    Rinaldo P; Studinski AL; Matern D
    Prenat Diagn; 2001 Jan; 21(1):52-4. PubMed ID: 11180241
    [No Abstract]   [Full Text] [Related]  

  • 42. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency.
    Stanley CA
    Adv Pediatr; 1987; 34():59-88. PubMed ID: 3318304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
    Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
    JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence that Oxidative Disbalance and Mitochondrial Dysfunction are Involved in the Pathophysiology of Fatty Acid Oxidation Disorders.
    Ribas GS; Vargas CR
    Cell Mol Neurobiol; 2022 Apr; 42(3):521-532. PubMed ID: 32876899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.
    Lund AM; Skovby F; Vestergaard H; Christensen M; Christensen E
    J Inherit Metab Dis; 2010 Oct; 33(5):495-500. PubMed ID: 20066495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathophysiology of fatty acid oxidation disorders.
    Bennett MJ
    J Inherit Metab Dis; 2010 Oct; 33(5):533-7. PubMed ID: 20824345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.
    Roe CR; Brunengraber H
    Mol Genet Metab; 2015 Dec; 116(4):260-8. PubMed ID: 26547562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Screening for fatty acid oxidation disorders of newborns in Zhejiang province:prevalence, outcome and follow-up].
    Zheng J; Zhang Y; Hong F; Yang J; Tong F; Mao H; Huang X; Zhou X; Yang R; Zhao Z; Huang X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 May; 46(3):248-255. PubMed ID: 29039165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel functional assay for simultaneous determination of total fatty acid beta-oxidation flux and acylcarnitine profiling in human skin fibroblasts using (2)H(31)-palmitate by isotope ratio mass spectrometry and electrospray tandem mass spectrometry.
    Law LK; Tang NL; Hui J; Ho CS; Ruiter J; Fok TF; Wanders RJ; Lam CW
    Clin Chim Acta; 2007 Jul; 382(1-2):25-30. PubMed ID: 17442290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of mitochondrial fatty acid β-oxidation in human: what can we learn from inborn fatty acid β-oxidation deficiencies?
    Bastin J
    Biochimie; 2014 Jan; 96():113-20. PubMed ID: 23764392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defects of mitochondrial beta-oxidation: a growing group of disorders.
    Vockley J; Whiteman DA
    Neuromuscul Disord; 2002 Mar; 12(3):235-46. PubMed ID: 11801395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.
    Spiekerkoetter U; Wood PA
    J Inherit Metab Dis; 2010 Oct; 33(5):539-46. PubMed ID: 20532823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Tandem mass spectrometry analysis and genetic diagnosis of neonates with fatty acid oxidation disorders in central and northern regions of Guangxi].
    Tan J; Chen D; Huang J; Chang R; Yan T; Cai R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Nov; 36(11):1067-1072. PubMed ID: 31703127
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnosis and management of defects of mitochondrial beta-oxidation.
    Vockley J; Singh RH; Whiteman DA
    Curr Opin Clin Nutr Metab Care; 2002 Nov; 5(6):601-9. PubMed ID: 12394635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimating the Prevalence of Rare Diseases: Long-Chain Fatty Acid Oxidation Disorders as an Illustrative Example.
    Kruger E; McNiven P; Marsden D
    Adv Ther; 2022 Jul; 39(7):3361-3377. PubMed ID: 35674971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Living on the edge: substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders.
    van Eunen K; Volker-Touw CM; Gerding A; Bleeker A; Wolters JC; van Rijt WJ; Martines AM; Niezen-Koning KE; Heiner RM; Permentier H; Groen AK; Reijngoud DJ; Derks TG; Bakker BM
    BMC Biol; 2016 Dec; 14(1):107. PubMed ID: 27927213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intestinal pseudo-obstruction as a manifestation of impaired mitochondrial fatty acid oxidation.
    Gilbert J; Ibdah JA
    Med Hypotheses; 2005; 64(3):586-9. PubMed ID: 15617873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New developments in the diagnosis and investigation of mitochondrial fatty acid oxidation disorders.
    Coates PM
    Eur J Pediatr; 1994; 153(7 Suppl 1):S49-56. PubMed ID: 7957387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disease mechanisms and protein structures in fatty acid oxidation defects.
    Gregersen N; Olsen RK
    J Inherit Metab Dis; 2010 Oct; 33(5):547-53. PubMed ID: 20151199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of serum and dried blood spot acylcarnitine profiles for detection of fatty acid β-oxidation disorders in adult patients with rhabdomyolysis.
    Al-Thihli K; Sinclair G; Sirrs S; Mezei M; Nelson J; Vallance H
    J Inherit Metab Dis; 2014 Mar; 37(2):207-13. PubMed ID: 23296367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.